Canton, OHNCT07247162Now EnrollingIRB Ready

Hypertension Clinical Trial in Canton, OH

Access cutting-edge hypertension treatment through this phase 4 clinical trial at a research site in Canton. Study-provided care at no cost to qualified participants.

Sponsored by RECORDATI GROUP

Quick Self-Assessment

See if you qualify for this Canton location

Preparing your pre-screening questions…

Expert Care in Canton

Access hypertension specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related hypertension treatment provided free

Apply for This Canton Location

Check if you qualify for this hypertension clinical trial in Canton, OH

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Canton

    Convenient for OH residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Canton site if eligible
  4. 4Begin participation

About This Hypertension Study in Canton

Osilodrostat has proven to be a safe and efficacious treatment for patients with CS. Demonstrating normalisation of hypercortisolaemia and in patients with hypertension and/or dysglycaemia clinically relevant and statistically significant reductions in blood pressure and glycaemia. This study aims at providing additional evidence on the safety, efficacy and appropriate dosing of osilodrostat in patients with CS, who have hypertension.

Sponsor: RECORDATI GROUP

Who Can Participate

Inclusion Criteria

Male or female ≥ 18 years of age
Able to provide and have provided signed written informed consent prior to study participation
Diagnosis of endogenous Cushing's Syndrome
mUFC values from two 24h urinary collections \> ULN and ≤ 2x ULN
Participants with uncontrolled hypertension on stable doses of BP lowering medications (for at least 4 weeks); qualifying BP measurements by ABPM taken prior to randomisation defined as: Average of 24h ABPM SBP ≥ 135 or DBP ≥ 85 mmHg
Participants under glucocorticoid replacement therapy can be recruited only if this therapy has been already stopped for at least seven days or 5 half-lives prior to screening, whichever was longer
Not taking any drug therapy for CS. The following minimum periods without these medications need to be completed before baseline assessments:
Steroidogenesis inhibitors (e.g. ketoconazole, metyrapone): 1 week
Mifepristone: 3 weeks
SC Pasireotide: 1 week
Pasireotide LAR: 3 months
Cabergoline: 4 weeks
Able to take oral medication and be willing to comply with the requirements of the study

Exclusion Criteria

Previously treated with osilodrostat less than 12 weeks prior to start of screening
Known hypersensitivity to osilodrostat
Presence of any severe and/or uncontrolled medical condition or other conditions that could affect participation in the study
Participants who are scheduled for a surgery to treat CS within 32 weeks of randomisation to the study drug
Presence of a known "long term" history of both hypertension and diabetes (defined as both hypertension and diabetes diagnosed \>10 years prior to the initial diagnosis of endogenous CS)
History of cyclic CS with fluctuating clinical manifestations
Participants with pseudo-CS
Participants with compression of the optic chiasm due to a macroadenoma or participants at high risk of compression of the optic chiasm (tumour within 2 mm of optic chiasm)
Participants who have undergone pituitary or adrenal surgery for Cushing's syndrome within 3 months prior to screening.
Pituitary radiation therapy within 3 years of screening
Ectopic ACTH syndrome or adrenocortical carcinoma with a life expectancy of \<3 years or receiving chemotherapy
Having received prior mitotane treatment
Participants who are shift workers or have conditions that can affect the measurement of late-night salivary cortisol (LNSC) or the LDDST
Poorly controlled diabetes mellitus with a baseline HbA1c \> 10.5%. Participants receiving glucose lowering medications must be on stable doses for at least 4 weeks prior screening.
Participants who are hypothyroid and not on adequate replacement therapy
History of major surgery/surgical therapy for any cause within 4 weeks before entering the study. Participants should have recovered from the surgery and be in good clinical condition before entering the study
Presence of bradycardia and/or QT-related exclusion criteria
Total bilirubin \> 1.5 x ULN and ALT or AST \> 3 x ULN
Participation in any clinical investigation within 4 weeks prior to screening or longer if required by local regulation (Use of an investigational drug within 4 weeks prior to dosing)
Occurrence of any significant acute illness within 3 weeks prior to dosing/randomisation
Female participants who are pregnant, intending to become pregnant or breastfeed during the study or lactating, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test
Women of childbearing potential (WOCBP) who are unwilling to use highly effective contraception methods
Potentially unreliable or vulnerable participants (e.g. person kept in detention) and those judged by the Investigator to be unsuitable for the study.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Canton?

Yes, this clinical trial (NCT07247162) has an active research site in Canton, OH that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Hypertension Treatment Options in Canton, OH

If you're searching for hypertension treatment options in Canton, OH, this clinical trial (NCT07247162) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Canton research site is actively enrolling participants for this phase 4 clinical trial. You'll receive care from experienced hypertension specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all hypertension clinical trials near you to find additional studies recruiting in your area.

More Hypertension Trials in Canton, OH

See all hypertension clinical trials recruiting in Canton — not just this study.

Browse Hypertension Trials in Canton →

Ready to Join in Canton?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Canton, OH